JO
RYZB

John Overdeck’s RayzeBio, Inc. Common Stock RYZB Stock Holding History

John Overdeck’s Portfolio RYZB Stock Details RYZB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-38,500
Closed -$855K – 3449
2023
Q3 		$855K Buy
+38,500
New +$808K ﹤0.01% 2022

Other funds holding RYZB

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

John Overdeck's RYZB Position: Q4 2023 in Review

John Overdeck sold out of RayzeBio, Inc. Common Stock (RYZB) in Q4 2023, closing a stake of 38,500 shares — an estimated $855K sold.

John Overdeck first reported a position in RYZB in Q3 2023 and held it in 1 quarter. The position peaked at $855K in Q3 2023. 107 funds tracked by Wall St. Rank hold RYZB as of Q4 2023.

  • John Overdeck reported no remaining RayzeBio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • John Overdeck sold 38,500 RayzeBio, Inc. Common Stock shares in Q4 2023, an estimated $855K.
  • John Overdeck first reported a position in RayzeBio, Inc. Common Stock in Q3 2023 and held it in 1 quarter.
  • John Overdeck's RayzeBio, Inc. Common Stock position peaked at $855K in Q3 2023.
  • 107 funds tracked by Wall St. Rank held RayzeBio, Inc. Common Stock as of Q4 2023.

Based on Two Sigma Investments's 13F filing for Q4 2023, filed 14 Feb 2024.